logo
logo
Alpha Teknova, Inc.

Alpha Teknova, Inc.

NASDAQ•TKNO
CEO: Mr. Stephen Gunstream
セクター: Healthcare
業種: Drug Manufacturers - Specialty & Generic
上場日: 2021-06-25
Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
連絡先情報
2451 Bert Dr., Hollister, CA, 95023, United States
831-637-1100
www.teknova.com
時価総額
$106.52M
PER (TTM)
-5.8
36.6
配当利回り
--
52週高値
$8.65
52週安値
$1.91
52週レンジ
1%
順位48Top 64.4%
3.3
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 3.3 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$10.45M+9.17%
直近4四半期の推移

EPS

-$0.08-52.94%
直近4四半期の推移

フリーCF

-$2.27M-5.15%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue Rises 7.2% Nine month revenue reached $30.54M, marking a $2.06M increase, primarily driven by Lab Essentials segment growth.
Gross Profit Nearly Doubles Nine month gross profit surged 99.8% to $10.20M; gross margin improved to 33.4% from 17.9%.
Operating Loss Significantly Narrows Net loss for nine months reduced by 40.5% to $12.50M, reflecting better cost management across operations.
Operating Expenses Decline Total operating expenses fell 11.9% to $22.56M for nine months, aided by workforce reduction savings.

リスク要因

Continued Operating Losses Incurred $12.50M net loss for nine months; company may never achieve or maintain future profitability.
Potential Stock Price Drop Large volume of outstanding common stock available for immediate resale risks significant market price decline.
Supplier Concentration Risk Relies on limited suppliers for raw materials; no long-term supply arrangements exist for critical components.
Economic Uncertainty Impact Inflation and interest rate changes create uncertainty, potentially causing customers to reduce or delay product orders.

見通し

Future Expense Increase Expected Expect operating expenses to increase due to ongoing activities like attracting personnel and expanding manufacturing capacity.
Capital Raising Flexibility Shelf registration effective July 2025 allows offering up to $225M in securities based on future capital needs.
Credit Facility Covenants Must meet minimum net revenue of $39.0M and minimum cash requirement of $8.0M under credit agreement.
Focus on Capacity Expansion Investing in infrastructure to improve efficiency, expand capacity at facilities, and build overall brand market presence.

同業比較

売上高 (TTM)

NeoGenomics, Inc.NEO
$727.33M
+10.1%
Ironwood Pharmaceuticals, Inc.IRWD
$338.99M
-10.4%
Canopy Growth CorporationCGC
$294.24M
+6.3%

粗利益率 (最新四半期)

ProQR Therapeutics N.V.PRQR
100.0%
+0.0pp
Ironwood Pharmaceuticals, Inc.IRWD
100.0%
+32.6pp
AC Immune SAACIU
100.0%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
IRWD$777.60M27.2-9.5%151.0%
CGC$560.83M-1.6-52.9%20.3%
CERS$455.25M-28.5-27.9%45.6%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
4.1%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月26日
|
EPS:-$0.09
|
売上高:$9.62M
財務レポート
財務データ
ニュース
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月7日|
    売上高: $10.45M+9.2%
    |
    EPS: $-0.08-52.9%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月8日|
    売上高: $10.29M+7.0%
    |
    EPS: $-0.07-48.6%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月9日|
    売上高: $9.80M+5.4%
    |
    EPS: $-0.09-56.5%
    予想を上回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月7日|
    売上高: $37.75M+2.9%
    |
    EPS: $-0.57+50.9%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月8日|
    売上高: $9.58M+17.2%
    |
    EPS: $-0.17-50.0%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月13日|
    売上高: $9.61M-16.6%
    |
    EPS: $-0.13-48.0%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月13日|
    売上高: $9.29M+1.9%
    |
    EPS: $-0.20-35.5%
    予想を上回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月27日|
    売上高: $36.68M-11.4%
    |
    EPS: $-1.16+31.4%
    予想を下回る